| Peer-Reviewed

Determinants of Cannabis Use Among Psychotics in Kinshasa, Democratic Republic of the Congo: A cross-sectional study

Received: 6 July 2021     Accepted: 22 July 2021     Published: 5 August 2021
Views:       Downloads:
Abstract

Background and aim: The relationship between cannabis use and psychosis is well established, but the determinants of this use in psychotics in developing countries are lacking. The aim of this study is to identify the determinants of cannabis use among psychotics in Kinshasa, Democratic Republic of Congo. Methods: This cross-sectional and analytical study included 321 psychotics carried at the Neuropsycho-pathological Center of the University of Kinshasa out from January 1, 2018 to December 31, 2019. The variables of interest were socio-demographic parameters, cannabis use and diagnoses of psychosis. A logistic regression model identified the determinants of cannabis use. The threshold of statistical significance was p<0.05. Results: The mean age of cannabis users was 30.9 ± 8.7 years with a sex ratio of 12 M / 1F. They represented 37% of psychotics of which 51% were of no religion and 55% were schizophrenics, 77% had tobacco-alcohol co-use, 83% had high education level and 78% were single. The determinants of cannabis use were male (aOR=2.01, 95% CI: 1.27-3.18; P<0.003), not belonging to a religion (aOR: 2.43, 95% CI: 1.24-4.80; p=0.010), tobacco co-consumption (aOR=9.12 95% CI: 4.35-19.13; p<0.001), alcohol (aOR=4.39, 95% CI: 2.22-8.71; p<0.001) and schizophrenia (aOR=2.29 95% CI: 1.15-3, 19.13; P=0.019). Conclusion: The prevalence of cannabis use among psychotics was high. They were young male schizophrenics, without religion, single with co-consumption of tobacco and alcohol. The determinants were male gender, non-religious affiliation, tobacco-alcohol co-consumption and schizophrenia.

Published in Journal of Drug Design and Medicinal Chemistry (Volume 7, Issue 3)
DOI 10.11648/j.jddmc.20210703.11
Page(s) 44-49
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Cannabis, Schizophrenia, Tobacco-alcohol Co-consumption

References
[1] Hequet, C., Murray, R., Linszen, D. et van Os, J. (2005). The environment and schizophrenia: The role of cannabis use. Schizophrenia Bulletin. 2005; 31, 3: 608-612.
[2] Semple, D. M., McIntosh, A. M. et Lawrie, S. M. Cannabis as a risk factor for psychosis: Systematic review. Journal of Psychopharmacology. 2005; 19, 2: 187-194.
[3] Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M. et Lewis, G. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet. 2007; 370, 9584: 319-328.
[4] Large M, Mullin K, Gupta P, Harris A, & Nielssen O. Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use. Aust N Z J Psychiatry. 2014; 48: 418-432.
[5] Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016; 42, 5: 1262-9.
[6] Myles H, Myles N, Large M. Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use. Australian & New Zealand Journal of Psychiatry. 2016; 50, 3: 208-19.
[7] Gage SH., Jones HJ, Burgess S, Bowden J, Davey Smith G., Zammit S, Munafo. Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study. Psychol Med. 2017; 47, 5: 971-980.
[8] Maag V. Dépénalisation de la consommation du cannabis: expériences en Europe occidentale, aux Etats-unis et en Australie. Drogues, santé et société 2004; 2, 2: 1-6.
[9] Goullé JP., Guerbet M. L’usage récréatif du cannabis: des effets aux méfaits. Données épidémiologiques. Bull Acad Natl Med. 2020; 204, 6: 543-550.
[10] American Psychiatric Association. Manuel diagnostique et statistique des troubles mentaux (DSM IV-TR).2013; 5e édition, Paris: Masson.
[11] Mifundu B. A. Profil socio-clinique des patients cannabiques hospitalisés aux CNPP/MA Mémoire de fin de spécialisation en neuropsychiatrie. Université de Kinshasa; 1995.
[12] Mifundu B. A., Mampunza M. M. S. Prise en charge des cannabiques en médecine traditionnelle à Kinshasa. Cas du Centre Mbemba Yulu, Congo médical. 1999; 11, 10: 687-690.
[13] Okitundu L. E. A., Mifundu B. A.. Cannabisme et troubles mentaux en milieu rural zaïrois. Aspects épidémiologiques. Médecine d’Afrique Noire, 1995; XXXII, 5 de mai 1995.
[14] Okitundu L. E. A., Mifundu B. A. Lusamba M. (1999). L’état de santé mentale des cannabiques et facteurs psychopathologiques en milieu rural au Kasai-Occidental (RDC) 1999; 11, 11: 775-760.
[15] Geus Ch., De Longueville X. et Schepens. Troubles psychotiques et usage de cannabis: Etude rétrospective. Louvain Médical 2004; 123: 14-17.
[16] Rodriguez-Jimenez R, Aragues M, Jimenez-Arriero MA, Ponce G, Munoz A, Bagney A, et al. Dual diagnosis in psychiatric inpatients: prevalence and general characteristics]. Invest Clin. 2008; 49, 2: 195-205.
[17] Guillem E, Pelissolo A., Vorspan F., Bouchez-Arbabzadeh S., Lépine J-P. Facteurs sociodémographiques, conduites addictives et comorbidité psychiatrique des usagers de cannabis vus en consultation spécialisée. L’ Encéphale 2009; 35, 3: 226-233.
[18] Koskinen, J., Lohonen, J., Koponen, H., Isohanni, M. et Miettunen, J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: A meta-analysis. Schizophrania Bulletin. 2010; 36, 6: 1115-1130.
[19] Institut National de la Santé et de la Recherche Médicale (INSERM). Synthèse et recommandations. «Cannabis. Quels effets sur le comportement et la santé?». Données réactualisées en 2004. Expertise collective. 2004, 4 pages.
[20] Lututala M. B. et Ngondo a P. Gender and Education for All: The Leap to Equality “Paper commissioned for the EFA Global Monitoring Report 2003/4, The Leap to Equality”. 2003, 11.
[21] Bruchon- schweitzer M. Psychologie de la santé: modèles, concepts et méthodes. Dunod, Paris 2002.
[22] Sanchez Z, Oliveira LG and Nappo SA. Religiosity as a protective factor against use of drugs. Substance use and misuse 2008; 43: 1476-1486.
[23] Petry NM, Lewis MW, Ostvik-White EM: Participation in religious activities during contingency management interventions is associated with substance use treatment outcomes. Am J Addict 2008; 17: 408-13.
[24] Ramo DE, Liu H, Prochaska JJ. Tobacco and marijuana use among adolescents and young adults: a systematic review of their co-use. Clinical Psychology Review. 2012; 32, 2: 105-121.
[25] Subbaraman MS, Kerr WC. Simultaneous versus concurrent use of alcohol and cannabis in the national alcohol survey. Alcohol Clin Exp Res. 2015; 39, 5: 872-9.
[26] Mifundu B. A., Mampunza M. M. S. Cannabisme et cannabique: Perception de l’entourage familial. Annales de l’IRS 1998; 2: 41-42.
[27] Ministère du Plan. Document de la Stratégie de Croissance et de Réduction de la Pauvreté, 2011, 92.
[28] Dussy FE, Hamberg C, Luginbuhl M, Schwerzmann T, Briellmann TA. Isolation of Delta9-THCA-A from hemp and analytical aspects concerning the determination of Delta9-THC in cannabis products. Forensic Sci Int. 2005; 149, 1: 3-10.
[29] Arpana Agrawal and Michael T. Lynskey. Tobacco and Cannabis Co-occurrence: Does Route of Administration Matter? Drug Alcohol Depend. 2009 January 1; 99, 1-3: 240-247.
[30] Kandel DB, Yamaguchi K, Chen K. Stages of progression in drug involvement from adolescence to adulthood: further evidence for the gateway theory. J Stud Alcohol. 1992; 53, 5: 447-457.
[31] Patton GC, Coffey C, Carlin JB, Sawyer SM, Lynskey M. Reverse gateways? Frequent cannabis use as a predictor of tobacco initiation and nicotine dependence. Addiction 2005; 100: 1518–1525.
[32] Power RA., Verweij KJ, Zuhair M, et al. Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry. 2014; 19, 11: 1201-1204.
[33] Agrawal A, Lynskey MT. Tobacco and cannabis co-occurrence: does route of administration matter? Drug Alcohol Depend. 2009; 99, (1-3): 240-247.
[34] Mueser KT, Yarnold PR, Levinson DF, et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr Bull. 1990; 16: 31–55.
[35] Hunt GE, Large MM, Cleary M, et al. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical setting, 1990-2007: systematic review and meta-analysis. Drug Alcool Depend. 2018; 191: 234-258.
[36] McLoughlin BC, Pushpa-Rajah JA, Gillies D, et al. Cannabis and schizophrenia. Cochrane Database Systt Rev. 20014; 10.
[37] Dervaux A, Laqueille X, Le Borgn MH et al Cannabis et schizophrénie: données cliniques et sociodémographiques, L’Encéphale 2003; 29: 11-17.
[38] Dervaux A., Krebs M-O., Laqueille X. Les troubles cognitifs et psychiatriques liés à la consommation de cannabis Bull. Acad. Natle Méd. 2014; 198, 3: 559-577.
[39] Potvin, S., Stip, E. & Roy, J.-Y.. Schizophrénie et cannabinoïdes: données cliniques, expérimentales et biologiques. Drogues, santé et société 2000; 2, 2.
Cite This Article
  • APA Style

    Abraham Bilongo Mifundu, Gilbert Lelo Mananga, Aliocha Natuhoyila Nkodila, Pelagie Babakazo, Gauthier Ehunu Messia, et al. (2021). Determinants of Cannabis Use Among Psychotics in Kinshasa, Democratic Republic of the Congo: A cross-sectional study. Journal of Drug Design and Medicinal Chemistry, 7(3), 44-49. https://doi.org/10.11648/j.jddmc.20210703.11

    Copy | Download

    ACS Style

    Abraham Bilongo Mifundu; Gilbert Lelo Mananga; Aliocha Natuhoyila Nkodila; Pelagie Babakazo; Gauthier Ehunu Messia, et al. Determinants of Cannabis Use Among Psychotics in Kinshasa, Democratic Republic of the Congo: A cross-sectional study. J. Drug Des. Med. Chem. 2021, 7(3), 44-49. doi: 10.11648/j.jddmc.20210703.11

    Copy | Download

    AMA Style

    Abraham Bilongo Mifundu, Gilbert Lelo Mananga, Aliocha Natuhoyila Nkodila, Pelagie Babakazo, Gauthier Ehunu Messia, et al. Determinants of Cannabis Use Among Psychotics in Kinshasa, Democratic Republic of the Congo: A cross-sectional study. J Drug Des Med Chem. 2021;7(3):44-49. doi: 10.11648/j.jddmc.20210703.11

    Copy | Download

  • @article{10.11648/j.jddmc.20210703.11,
      author = {Abraham Bilongo Mifundu and Gilbert Lelo Mananga and Aliocha Natuhoyila Nkodila and Pelagie Babakazo and Gauthier Ehunu Messia and Samuel Ma-Miezi Mampunza},
      title = {Determinants of Cannabis Use Among Psychotics in Kinshasa, Democratic Republic of the Congo: A cross-sectional study},
      journal = {Journal of Drug Design and Medicinal Chemistry},
      volume = {7},
      number = {3},
      pages = {44-49},
      doi = {10.11648/j.jddmc.20210703.11},
      url = {https://doi.org/10.11648/j.jddmc.20210703.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jddmc.20210703.11},
      abstract = {Background and aim: The relationship between cannabis use and psychosis is well established, but the determinants of this use in psychotics in developing countries are lacking. The aim of this study is to identify the determinants of cannabis use among psychotics in Kinshasa, Democratic Republic of Congo. Methods: This cross-sectional and analytical study included 321 psychotics carried at the Neuropsycho-pathological Center of the University of Kinshasa out from January 1, 2018 to December 31, 2019. The variables of interest were socio-demographic parameters, cannabis use and diagnoses of psychosis. A logistic regression model identified the determinants of cannabis use. The threshold of statistical significance was pResults: The mean age of cannabis users was 30.9 ± 8.7 years with a sex ratio of 12 M / 1F. They represented 37% of psychotics of which 51% were of no religion and 55% were schizophrenics, 77% had tobacco-alcohol co-use, 83% had high education level and 78% were single. The determinants of cannabis use were male (aOR=2.01, 95% CI: 1.27-3.18; PConclusion: The prevalence of cannabis use among psychotics was high. They were young male schizophrenics, without religion, single with co-consumption of tobacco and alcohol. The determinants were male gender, non-religious affiliation, tobacco-alcohol co-consumption and schizophrenia.},
     year = {2021}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Determinants of Cannabis Use Among Psychotics in Kinshasa, Democratic Republic of the Congo: A cross-sectional study
    AU  - Abraham Bilongo Mifundu
    AU  - Gilbert Lelo Mananga
    AU  - Aliocha Natuhoyila Nkodila
    AU  - Pelagie Babakazo
    AU  - Gauthier Ehunu Messia
    AU  - Samuel Ma-Miezi Mampunza
    Y1  - 2021/08/05
    PY  - 2021
    N1  - https://doi.org/10.11648/j.jddmc.20210703.11
    DO  - 10.11648/j.jddmc.20210703.11
    T2  - Journal of Drug Design and Medicinal Chemistry
    JF  - Journal of Drug Design and Medicinal Chemistry
    JO  - Journal of Drug Design and Medicinal Chemistry
    SP  - 44
    EP  - 49
    PB  - Science Publishing Group
    SN  - 2472-3576
    UR  - https://doi.org/10.11648/j.jddmc.20210703.11
    AB  - Background and aim: The relationship between cannabis use and psychosis is well established, but the determinants of this use in psychotics in developing countries are lacking. The aim of this study is to identify the determinants of cannabis use among psychotics in Kinshasa, Democratic Republic of Congo. Methods: This cross-sectional and analytical study included 321 psychotics carried at the Neuropsycho-pathological Center of the University of Kinshasa out from January 1, 2018 to December 31, 2019. The variables of interest were socio-demographic parameters, cannabis use and diagnoses of psychosis. A logistic regression model identified the determinants of cannabis use. The threshold of statistical significance was pResults: The mean age of cannabis users was 30.9 ± 8.7 years with a sex ratio of 12 M / 1F. They represented 37% of psychotics of which 51% were of no religion and 55% were schizophrenics, 77% had tobacco-alcohol co-use, 83% had high education level and 78% were single. The determinants of cannabis use were male (aOR=2.01, 95% CI: 1.27-3.18; PConclusion: The prevalence of cannabis use among psychotics was high. They were young male schizophrenics, without religion, single with co-consumption of tobacco and alcohol. The determinants were male gender, non-religious affiliation, tobacco-alcohol co-consumption and schizophrenia.
    VL  - 7
    IS  - 3
    ER  - 

    Copy | Download

Author Information
  • Neuropsychopathological Center, University of Kinshasa, Kinshasa, Democratic Republic of the Congo

  • Neuropsychopathological Center, University of Kinshasa, Kinshasa, Democratic Republic of the Congo

  • Faculty of Family Medicine, Protestant University in Congo, Kinshasa, Democratic Republic of the Congo

  • Neuropsychopathological Center, University of Kinshasa, Kinshasa, Democratic Republic of the Congo

  • Faculty of Pharmacy, University of Kinshasa, Kinshasa, Democratic Republic of the Congo

  • Neuropsychopathological Center, University of Kinshasa, Kinshasa, Democratic Republic of the Congo

  • Sections